Role of hyperthermic perfusion in the treatment of limb osteogenic sarcoma

R. Cavaliere, F. Di Filippo, F. S. Santori, L. Piarulli, S. Carlini, A. Calabrò, M. Pagliarin, F. Cavaliere, P. Cerulli, G. Monticelli

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The role of hyperthermic perfusion (HP) for the treatment of limb osteogenic sarcoma was evaluated in 76 patients. Twelve patients were treated with HP alone, and a 5-and 10-year survival rate of 25.5% was obtained. When amputation was systematically associated to HP (12 patients), a 5-and 10-year survival rate of 50.9% was achieved. Twenty-seven patients were treated with hyperthermic antiblastic perfusion (HAP) followed by amputation 4 weeks later. With this treatment, the 5-and 10-year actuarial rates rose to 71.4 and 65%, respectively, with a 5-year disease-free survival rate of 67.4%. Fifteen patients were treated with HAP followed by an ‘en bloc’ resection and bone reconstruction. The 5-and 10-year actuarial survival rate obtained was 63.5% with a 5-year disease-free survival rate of 53.6%. These results seem to indicate that HAP permits carrying out conservative rather than ablative surgery for the treatment of limb osteogenic sarcoma.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalOncology
Volume44
Issue number1
DOIs
Publication statusPublished - 1987

Fingerprint

Osteosarcoma
Extremities
Perfusion
Survival Rate
Amputation
Disease-Free Survival
Therapeutics
Bone and Bones

Keywords

  • Hyperthermia
  • Hyperthermic perfusion
  • Osteogenic sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cavaliere, R., Di Filippo, F., Santori, F. S., Piarulli, L., Carlini, S., Calabrò, A., ... Monticelli, G. (1987). Role of hyperthermic perfusion in the treatment of limb osteogenic sarcoma. Oncology, 44(1), 1-5. https://doi.org/10.1159/000226433

Role of hyperthermic perfusion in the treatment of limb osteogenic sarcoma. / Cavaliere, R.; Di Filippo, F.; Santori, F. S.; Piarulli, L.; Carlini, S.; Calabrò, A.; Pagliarin, M.; Cavaliere, F.; Cerulli, P.; Monticelli, G.

In: Oncology, Vol. 44, No. 1, 1987, p. 1-5.

Research output: Contribution to journalArticle

Cavaliere, R, Di Filippo, F, Santori, FS, Piarulli, L, Carlini, S, Calabrò, A, Pagliarin, M, Cavaliere, F, Cerulli, P & Monticelli, G 1987, 'Role of hyperthermic perfusion in the treatment of limb osteogenic sarcoma', Oncology, vol. 44, no. 1, pp. 1-5. https://doi.org/10.1159/000226433
Cavaliere R, Di Filippo F, Santori FS, Piarulli L, Carlini S, Calabrò A et al. Role of hyperthermic perfusion in the treatment of limb osteogenic sarcoma. Oncology. 1987;44(1):1-5. https://doi.org/10.1159/000226433
Cavaliere, R. ; Di Filippo, F. ; Santori, F. S. ; Piarulli, L. ; Carlini, S. ; Calabrò, A. ; Pagliarin, M. ; Cavaliere, F. ; Cerulli, P. ; Monticelli, G. / Role of hyperthermic perfusion in the treatment of limb osteogenic sarcoma. In: Oncology. 1987 ; Vol. 44, No. 1. pp. 1-5.
@article{8dd41d22d2174ea8b77632fb94f77b1c,
title = "Role of hyperthermic perfusion in the treatment of limb osteogenic sarcoma",
abstract = "The role of hyperthermic perfusion (HP) for the treatment of limb osteogenic sarcoma was evaluated in 76 patients. Twelve patients were treated with HP alone, and a 5-and 10-year survival rate of 25.5{\%} was obtained. When amputation was systematically associated to HP (12 patients), a 5-and 10-year survival rate of 50.9{\%} was achieved. Twenty-seven patients were treated with hyperthermic antiblastic perfusion (HAP) followed by amputation 4 weeks later. With this treatment, the 5-and 10-year actuarial rates rose to 71.4 and 65{\%}, respectively, with a 5-year disease-free survival rate of 67.4{\%}. Fifteen patients were treated with HAP followed by an ‘en bloc’ resection and bone reconstruction. The 5-and 10-year actuarial survival rate obtained was 63.5{\%} with a 5-year disease-free survival rate of 53.6{\%}. These results seem to indicate that HAP permits carrying out conservative rather than ablative surgery for the treatment of limb osteogenic sarcoma.",
keywords = "Hyperthermia, Hyperthermic perfusion, Osteogenic sarcoma",
author = "R. Cavaliere and {Di Filippo}, F. and Santori, {F. S.} and L. Piarulli and S. Carlini and A. Calabr{\`o} and M. Pagliarin and F. Cavaliere and P. Cerulli and G. Monticelli",
year = "1987",
doi = "10.1159/000226433",
language = "English",
volume = "44",
pages = "1--5",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - Role of hyperthermic perfusion in the treatment of limb osteogenic sarcoma

AU - Cavaliere, R.

AU - Di Filippo, F.

AU - Santori, F. S.

AU - Piarulli, L.

AU - Carlini, S.

AU - Calabrò, A.

AU - Pagliarin, M.

AU - Cavaliere, F.

AU - Cerulli, P.

AU - Monticelli, G.

PY - 1987

Y1 - 1987

N2 - The role of hyperthermic perfusion (HP) for the treatment of limb osteogenic sarcoma was evaluated in 76 patients. Twelve patients were treated with HP alone, and a 5-and 10-year survival rate of 25.5% was obtained. When amputation was systematically associated to HP (12 patients), a 5-and 10-year survival rate of 50.9% was achieved. Twenty-seven patients were treated with hyperthermic antiblastic perfusion (HAP) followed by amputation 4 weeks later. With this treatment, the 5-and 10-year actuarial rates rose to 71.4 and 65%, respectively, with a 5-year disease-free survival rate of 67.4%. Fifteen patients were treated with HAP followed by an ‘en bloc’ resection and bone reconstruction. The 5-and 10-year actuarial survival rate obtained was 63.5% with a 5-year disease-free survival rate of 53.6%. These results seem to indicate that HAP permits carrying out conservative rather than ablative surgery for the treatment of limb osteogenic sarcoma.

AB - The role of hyperthermic perfusion (HP) for the treatment of limb osteogenic sarcoma was evaluated in 76 patients. Twelve patients were treated with HP alone, and a 5-and 10-year survival rate of 25.5% was obtained. When amputation was systematically associated to HP (12 patients), a 5-and 10-year survival rate of 50.9% was achieved. Twenty-seven patients were treated with hyperthermic antiblastic perfusion (HAP) followed by amputation 4 weeks later. With this treatment, the 5-and 10-year actuarial rates rose to 71.4 and 65%, respectively, with a 5-year disease-free survival rate of 67.4%. Fifteen patients were treated with HAP followed by an ‘en bloc’ resection and bone reconstruction. The 5-and 10-year actuarial survival rate obtained was 63.5% with a 5-year disease-free survival rate of 53.6%. These results seem to indicate that HAP permits carrying out conservative rather than ablative surgery for the treatment of limb osteogenic sarcoma.

KW - Hyperthermia

KW - Hyperthermic perfusion

KW - Osteogenic sarcoma

UR - http://www.scopus.com/inward/record.url?scp=0023149120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023149120&partnerID=8YFLogxK

U2 - 10.1159/000226433

DO - 10.1159/000226433

M3 - Article

VL - 44

SP - 1

EP - 5

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1

ER -